The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients
Tóm tắt
A few studies have reported the safety of the treatment of elderly osteoporotic patients with chronic kidney disease (CKD) and the possibility of hypocalcemia. The aim of the present study was to examine the relationship between the incidence of hypocalcemia and the CKD stage in elderly osteoporotic patients treated with denosumab. This study was designed as a parallel-group comparison study between the denosumab-associated hypocalcemia (DAH) groups: the concentration of serum calcium was under 8.6 mg/dl and the normal calcium (NC) groups: the concentration of serum calcium was over 8.6 mg/dl. Fifty-two subjects over 70 years old were enrolled in this study, with 16 patients classified into the DAH group and 36 patients assigned to the NC group. All patients were further classified into two subgroups according to their age, into an around 75 years group to clarify the relevance of old age and an around 85 years group and also into a mild CKD group and a moderate CKD group by based on estimated glomerular filtration (eGFR). Serum calcium concentration, tartrate-resistant acid phosphatase (TRACP-5b), and type 1 procollagen N terminal propeptide (P1NP) were measured, and adverse drug reactions were evaluated. The eGFR and serum calcium were significantly lower in the DAH group than in the NC group in the starting phase. Moreover, TRACP-5b was significantly higher in the DAH group than in the NC group in the starting phase. There were no significant differences in P1NP. The incidence of hypocalcemia was significantly higher in the around 85 groups than in the around 75 groups. The frequency of hypocalcemia was also significantly higher in the severe CKD group than in the mild CKD group. Advanced age combined with low eGFR and low serum Ca status appear to be associated with the incidence of hypocalcemia when using denosumab for the treatment of osteoporosis.
Tài liệu tham khảo
Block GA, Bone HG, Liang F, Edward L, Desmond O (2012) A Single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479
Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393
Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonate in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4:221–233
Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Eng J Med 349:1676–1679
Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, Kendler D, Messina O, Miller PD (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 23:397–409
Hiramatsu R, Ubara Y, Sawa N, Sakai A (2021) Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-tear observational study. Nephrol Dial Transplant.36:1900-1907. https://doi.org/10.1093/ndt/gfaa359
Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C for the FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med 361:756–765
Papapoulos P, Chapurlat R, Libanati C, Brandi ML, Brown JP et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the freedom extension. J Bone Miner Res 27:694–701
Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Papacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291–1299
Genant HK, Jergas M, Palermo L et al (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984–996
Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M (2018) Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int. https://doi.org/10.1007/s00198-018-4688-1
Kosaku N, Aiji Y, Ken T (2017) Management of osteoporosis in chronic kidney disease. Intern Med 56:3271–3276
Huynh ALH, Scott TB, Stewardson AJ, Johnson DF (2016) Denosumab-associated hypocalcaemia, severity and patient characteristics in a tertiary hospital setting. Pharm Drug Saf 25:1274–1278
Takuya I, Kimie S, Mayu T, Katsuhito H, Masao K, Kazuki F, Katsunori S, Michio K, Junichi K, Yoshiro S (2019) Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia. J Clin Pharm Ther 44:6268
Miller PD (2014) REVEW: chronic kidney disease and osteoporosis: evaluation and management. BoneKEY Rep. https://doi.org/10.1038/bonekey
Jalleh R, Basu G, LeLeu R, Jesudason S (2018) Case series: denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep Nephrol. https://doi.org/10.1155/2018/7384763
Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy C (2010) Kidney bone disease and mortality in CKD: revisiting the role of Vitamin D, alkaline phosphatase and minerals. Kidney Int Suppl 117:S10–S21
Ketteler M, Block GA, Evenepoel P, Fukunaga M, Herzog C, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD=MBD) Guideline Update: what’s changed and why it matters. Kidney Int 92:26–36
Lechner B, Deangelis C, Jamal N (2014) The effects of denosumab on calcium profiles in advanced cancer patients with bone metastasis. Support Care Cancer 22:1765–1771
Yonemori K, Fujisawa Y, Minami H (2008) Phase 1 trial of denosumab safety, pharmacokinetics and pharmacodynamics in Japanese women with breast cancer-related bone metastasis. Cancer Sci 99:1237–1242
Ishikawa K, Nagai T, Sakamoto K (2016) High bone turnover elevates the risk of denosumab-induced hypocalcaemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831–1840